Loss Contingency, Additional Unpatentable Patents , Number

No definition available.

Name:	mrk_LossContingencyAdditionalUnpatentablePatentsNumber
Namespace Prefix:	mrk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Patents Unpatentable, Number

+ References

No definition available.

+ Details

Name:	mrk_LossContingencyPatentsUnpatentableNumber
Namespace Prefix:	mrk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Regulatory Stay Duration

+ References

No definition available.

+ Details

Name:	mrk_LossContingencyRegulatoryStayDuration
Namespace Prefix:	mrk_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LitigationReserve
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482645/405-30-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.W.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479583/944-40-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity has allegedly infringed.

+ References

+ Details

Name:	us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of pending claims pertaining to a loss contingency.

+ References

+ Details

Name:	us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_Dr.SchollsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=mrk_MotionForSummaryJudgementGrantedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=us-gaap_PatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_SubcutaneousPembrolizumabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=mrk_PGRPetitionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=mrk_PGRPetitionProcessIneligibleToBeChallengedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_LynparzaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Contingencies (Details) $ in Millions			1 Months Ended	2 Months Ended	5 Months Ended
Contingencies (Details) $ in Millions	Jun. 12, 2026	Apr. 24, 2025 patent	Jun. 30, 2025 patent	May 31, 2023 patent	Oct. 31, 2025 patent	Oct. 31, 2024 patent	Jun. 30, 2026 USD ($) case	Dec. 31, 2025 USD ($)	Mar. 11, 2025 case
Legal Defense Costs
Loss Contingencies [Line Items]
Legal defense costs reserve \| $							$ 275	$ 245
Dr. Scholl's \| U.S. \| Pending Litigation
Loss Contingencies [Line Items]
Loss contingency, pending claims \| case							800
Gardasil/Gardasil 9 \| U.S. \| Motion for Summary Judgement Granted
Loss Contingencies [Line Items]
Loss contingency, pending claims \| case									16
Gardasil/Gardasil 9 \| Non-US \| Pending Litigation
Loss Contingencies [Line Items]
Loss contingency, pending claims \| case							15
Keytruda \| Pending Litigation \| Patents
Loss Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed				9		9
Number of unpatentable patents					9
Subcutaneous Pembrolizumab \| Pending Litigation \| Patents
Loss Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed		15
Subcutaneous Pembrolizumab \| Pending Litigation \| Patents - PGR Petition
Loss Contingencies [Line Items]
Loss contingency, pending claims			13
Number of unpatentable patents			4
Number of additional patents unpatentable			1
Subcutaneous Pembrolizumab \| Pending Litigation \| PGR Petition Process, Ineligible to be Challenged
Loss Contingencies [Line Items]
Loss contingency, pending claims		3
Lynparza \| Pending Litigation \| Patents
Loss Contingencies [Line Items]
Loss contingency, regulatory stay duration	30 months